31 March 2020
The ABN guidelines are suggesting that most high efficacy DMTs are treated the same. The MS Academy hosted a debate on 31 March 2020 to discuss whether ocrelizumab and cladribine should be treated in the same way as alemtuzumab in terms of risk of #COVID19. 

Please note that all session and slide content are the views of the Speakers, not the MS Academy. The content of the recording is the speaker’s personal opinion at the time of recording. Due to the everchanging situation, advice given at the time of recording is subject to change.

Chairs:
Prof Klaus Schmierer, Professor of Neurology, Barts and The London School of Medicine and Dentistry
Prof David Baker, Professor of Neuroimmunology, Barts and The London School of Medicine and Dentistry

Video and presentation slides available here: https://multiplesclerosisacademy.org/2020/04/01/webinar-debate-should-ocrelizumab-and-cladribine-be-treated-in-the-same-way-as-alemtuzumab-in-terms-of-covid-19/

This meeting has been sponsored by Roche Products Limited. Roche Products Limited has had no control over the educational content of this activity.

Should ocrelizumab & cladribine be treated the same way as alemtuzumab in terms of risk of COVID-19?

The Neurology Academy is an innovative training programme helping you to hone your expertise within our Academy specialities. 
We are an education provider for clinicians, specialist nurses and professions allied to medicine and the training focus is on both disease management and service transformation.